Stem cells international · 2025
iPSC-Derived MSC Secretome as a Protective and Restorative Modality for Atopic Dermatitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoo Seungah, Baek Hyun Jin, Park Narae, Nam Yoojun, Rim Yeri Alice, Ju Ji Hyeon
Аннотация
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts quality of life. Reducing inflammation and restoring the skin barrier are key to its management.
OBJECTIVE: This study aimed to investigate the protective and therapeutic effects of secretory substances from induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs) in AD.
METHODS: The protective effects of iMSC secretome pretreatment were evaluated in HaCaT cells by assessing cell viability, AD biomarker expression, and cell migration. Therapeutic efficacy was examined in a 1-chloro-2,4-dinitrobenzene (DNCB)-induced AD mouse model through clinical, histological, and immunological assessments. Proteomic analyses were performed to relevant biological processes.
RESULTS: iMSC secretome significantly reduced AD-induced cell death and AD biomarker expressions in vitro (p < 0.05), with 200 μg/mL iMSC secretome promoting cell migration. In vivo, high dose (20 mg/mL) iMSC secretome alleviate clinical indicators compared to the vehicle group (p < 0.05). Serum immunoglobulin (Ig) E, interleukin (IL)-4, IL-31, and IL-6 levels, along with the expression of AD biomarkers in skin, were significantly decreased (p < 0.05). Proteomic analyses revealed upregulation of genes involved in the regulation of immune responses and the restoration of skin barrier.
CONCLUSION: iMSC secretome demonstrates significant anti-inflammatory and regenerative effects, making it a promising therapeutic option for AD.
OBJECTIVE: This study aimed to investigate the protective and therapeutic effects of secretory substances from induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs) in AD.
METHODS: The protective effects of iMSC secretome pretreatment were evaluated in HaCaT cells by assessing cell viability, AD biomarker expression, and cell migration. Therapeutic efficacy was examined in a 1-chloro-2,4-dinitrobenzene (DNCB)-induced AD mouse model through clinical, histological, and immunological assessments. Proteomic analyses were performed to relevant biological processes.
RESULTS: iMSC secretome significantly reduced AD-induced cell death and AD biomarker expressions in vitro (p < 0.05), with 200 μg/mL iMSC secretome promoting cell migration. In vivo, high dose (20 mg/mL) iMSC secretome alleviate clinical indicators compared to the vehicle group (p < 0.05). Serum immunoglobulin (Ig) E, interleukin (IL)-4, IL-31, and IL-6 levels, along with the expression of AD biomarkers in skin, were significantly decreased (p < 0.05). Proteomic analyses revealed upregulation of genes involved in the regulation of immune responses and the restoration of skin barrier.
CONCLUSION: iMSC secretome demonstrates significant anti-inflammatory and regenerative effects, making it a promising therapeutic option for AD.